• Experts examine latest research on the efficacy of combination therapies for type 2 diabetes

    Experts examine latest research on the efficacy of combination therapies for type 2 diabetes

    A panel of physician-scientists including Ralph A. DeFronzo, MD, Chantal Mathieu, MD, PhD, Tina Vilsbøll, MD, DMSc, and David D’Alessio, MD, discussed the current evidence for combination therapies in the treatment of type 2 diabetes.

  • SGLT2 inhibitors demonstrate efficacy against CVD and kidney disease

    SGLT2 inhibitors demonstrate efficacy against CVD and kidney disease

    Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC, Muthiah Vaduganathan, MD, MPH, Brendon Neuen, MBBS (Hons), MSc (Oxon), and David C. Wheeler, MD, FRCP, reviewed recent trial results demonstrating the safety and efficacy of SGLT2 inhibitors for both cardiovascular and renal treatment, and discussed how those trial results will help improve care for people…

  • Diabetic neuropathy presents unique research challenges

    Diabetic neuropathy presents unique research challenges

    Nigel A. Calcutt, PhD, Fabiana Picconi, MD, Karolina S. Khan, MD, PhD, and Kara R. Mizokami-Stout, MD, made up a panel of researchers who discussed some of the most challenging issues they face while investigating methods to prevent and treat diabetic neuropathies.

  • Regulatory barriers put U.S. behind in adoption of islet transplantation for type 1 diabetes

    Regulatory barriers put U.S. behind in adoption of islet transplantation for type 1 diabetes

    Camillo Ricordi, MD, FNAI, Thierry Berney, MD, A.M. James Shapiro, MD, PhD, and Piotr Witkowski, MD, PhD, explained what has led to pancreatic islet transplantation effectively halting in the United States while the procedure has become standard of care in much of the rest of the world.

  • Social stress reverberates throughout overall wellness

    Social stress reverberates throughout overall wellness

    “Stress is epidemic in the U.S. and other Western [countries], and most of our stressors are social,” said Carol A. Shively, PhD, in a session on the influence of social stress and social inequalities on metabolic health. She presented evidence based on animal models. Mika Kivimäki, PhD, FMedSci, presented evidence of the correlation between socioeconomic…

  • Head-to-head outcomes trial finds few differences between common type 2 diabetes medications

    Head-to-head outcomes trial finds few differences between common type 2 diabetes medications

    Investigators presented findings from the GRADE study comparing clinical outcomes of glimepiride, a sulfonylurea; sitagliptin, a DPP-4 inhibitor; insulin Lantus; and liraglutide, a GLP-1 receptor agonist. More than 70% of participants reached the primary metabolic endpoint.

  • Dual SGLT1/SGLT2 inhibitor shows significant cardiovascular benefits in patients with CV conditions and type 2 diabetes

    Dual SGLT1/SGLT2 inhibitor shows significant cardiovascular benefits in patients with CV conditions and type 2 diabetes

    An analysis of the SCORED and SOLOIST trials favored sotagliflozin over placebo for total cardiovascular death, hospitalization for heart failure, and urgent heart failure visit. The combined SGLT1/SGLT2 inhibitor produces benefits in patients with reduced and preserved ejection fraction, said Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC.

  • Dual GIP/GLP-1 receptor agonist lowers glucose, reduces body weight in SURPASS trials

    Dual GIP/GLP-1 receptor agonist lowers glucose, reduces body weight in SURPASS trials

    “The road ahead for the treatment of type 2 diabetes is fresh,” said Alice Y.Y. Cheng, MD. “The future, in terms of what we will be able to offer our patients to help them meet their metabolic goals, appears to be very positive.”

  • AMPLITUDE-O investigators report good CV, renal, safety outcomes for efpeglenatide

    AMPLITUDE-O investigators report good CV, renal, safety outcomes for efpeglenatide

    The efficacy and safety outcomes of efpeglenatide are similar to the outcomes seen in trials of other GLP-1 receptor agonists, according to researchers who presented AMPLITUDE-O data at the Scientific Sessions.

  • DARE-19 shows dapagliflozin does not improve outcomes in COVID-19 patients

    DARE-19 shows dapagliflozin does not improve outcomes in COVID-19 patients

    DARE-19 was the first large, randomized clinical trial of an SGLT2 inhibitor to address the potential benefits of these agents in patients hospitalized with COVID-19. Results showed no significant effect on organ failure or survival. Mikhail N. Kosiborod, MD, was the principal investigator.

0